Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Praxis Precision Medicines stock

Own Praxis Precision Medicines stock in just a few minutes.

Praxis Precision Medicines, Inc is a biotechnology business based in the US. Praxis Precision Medicines shares (PRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Praxis Precision Medicines employs 67 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Praxis Precision Medicines

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRAX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Praxis Precision Medicines share price

Use our graph to track the performance of PRAX stocks over time.

Praxis Precision Medicines shares at a glance

Information last updated 2021-04-23.
52-week range$19.00 - $60.95
50-day moving average $33.43
200-day moving average $41.74
Wall St. target price$66.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Praxis Precision Medicines shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Praxis Precision Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Praxis Precision Medicines financials

Gross profit TTM $0
Return on assets TTM -22.08%
Return on equity TTM -37.75%
Profit margin 0%
Book value N/A
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Praxis Precision Medicines shares

There are currently 2.0 million Praxis Precision Medicines shares held short by investors – that's known as Praxis Precision Medicines's "short interest". This figure is 129.6% up from 881,717 last month.

There are a few different ways that this level of interest in shorting Praxis Precision Medicines shares can be evaluated.

Praxis Precision Medicines's "short interest ratio" (SIR)

Praxis Precision Medicines's "short interest ratio" (SIR) is the quantity of Praxis Precision Medicines shares currently shorted divided by the average quantity of Praxis Precision Medicines shares traded daily (recently around 204455.25252525). Praxis Precision Medicines's SIR currently stands at 9.9. In other words for every 100,000 Praxis Precision Medicines shares traded daily on the market, roughly 9900 shares are currently held short.

To gain some more context, you can compare Praxis Precision Medicines's short interest ratio against those of similar companies.

However Praxis Precision Medicines's short interest can also be evaluated against the total number of Praxis Precision Medicines shares, or, against the total number of tradable Praxis Precision Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Praxis Precision Medicines's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Praxis Precision Medicines shares in existence, roughly 50 shares are currently held short) or 0.0903% of the tradable shares (for every 100,000 tradable Praxis Precision Medicines shares, roughly 90 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Praxis Precision Medicines.

Find out more about how you can short Praxis Precision Medicines stock.

Praxis Precision Medicines share dividends

We're not expecting Praxis Precision Medicines to pay a dividend over the next 12 months.

You may also wish to consider:

Praxis Precision Medicines overview

Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc. ; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. ; and collaboration with The Florey Institute to develop three novel ASOs.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site